Legend Capital has made the first close of the third USD-denominated China healthcare fund at $177 million. In a separate development, Ustar Biotechnologies (Hangzhou) has raised over 300 million yuan ($47 million) in its Series E+ round of financing.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
